治疗慢性乙型肝炎

P. Pramita, R. Gani, A. Sulaiman
{"title":"治疗慢性乙型肝炎","authors":"P. Pramita, R. Gani, A. Sulaiman","doi":"10.24871/6120059-15","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic HBV (Hepatitis B virus) infection had not shown satisfactory Result. Monotherapy with alpha interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance. The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination therapy should be considered if there is no sufficient response to monotherapy. Keywords : Treatment, chronic hepatitis B, combination therapy","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2005-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of chronic hepatitis B\",\"authors\":\"P. Pramita, R. Gani, A. Sulaiman\",\"doi\":\"10.24871/6120059-15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic HBV (Hepatitis B virus) infection had not shown satisfactory Result. Monotherapy with alpha interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance. The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination therapy should be considered if there is no sufficient response to monotherapy. Keywords : Treatment, chronic hepatitis B, combination therapy\",\"PeriodicalId\":51267,\"journal\":{\"name\":\"Nature Clinical Practice. Gastroenterology & Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Clinical Practice. Gastroenterology & Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24871/6120059-15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Clinical Practice. Gastroenterology & Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24871/6120059-15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

慢性乙型肝炎在印度尼西亚仍然是一个主要的健康问题。不幸的是,迄今为止,慢性HBV(乙型肝炎病毒)感染的治疗并未显示出令人满意的结果。干扰素或拉米夫定的单药治疗已被广泛用于慢性HBV的治疗。然而,亚洲人对α干扰素的治疗反应并不令人满意(15% - 20%),而拉米夫定单药治疗不足以根除慢性感染患者的HBV,而且通常会引起耐药性。慢性乙型肝炎对拉米夫定耐药的发生促进了阿德福韦、恩替卡韦、恩曲他滨和核苷类似物等新药的开发。如果对单药治疗没有足够的反应,应考虑采用联合治疗的新治疗策略。关键词:治疗,慢性乙型肝炎,联合治疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Treatment of chronic hepatitis B
Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic HBV (Hepatitis B virus) infection had not shown satisfactory Result. Monotherapy with alpha interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance. The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination therapy should be considered if there is no sufficient response to monotherapy. Keywords : Treatment, chronic hepatitis B, combination therapy
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Introducci|[oacute]|n Portación crónica de VHB, HBeAg negativo Nuevas estrategias de tratamiento en la hepatitis B crónica Hombre de 42 años con hepatitis B crónica, HBeAg positivo Tratamiento de la hepatitis B grave en el contexto del pre y pos trasplante hepático
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1